Abliva AB

Pharming Group N.V. announced a recommended public cash offer to acquire Abliva AB, valuing the transaction at approximately US$66.1 million. Abliva’s lead product, KL1333, is in a pivotal clinical trial for mitochondrial DNA-driven primary mitochondrial diseases, with a positive interim analysis. The acquisition strengthens Pharming’s late-stage pipeline and aligns with its vision to become a leading global rare disease company.

Pharming Group N.V. announced a public cash offer to acquire all shares of Abliva AB for SEK 0.45 per share, valued at US$66.1 million. Abliva's Board recommended shareholders accept the offer, with the acceptance period expected from January 16 to February 7, 2025. Abliva's KL1333 is in a pivotal clinical trial for mitochondrial diseases.